Deleterious effects of cardiopulmonary bypass. A prospective study of bubble versus membrane oxygenation.

[1]  C. Wildevuur,et al.  A new hollow fiber membrane oxygenator with an integral heat exchanger: a hematological evaluation in dogs. , 1983, The Thoracic and cardiovascular surgeon.

[2]  J. Fehr,et al.  In vivo complement activation by polyanion--polycation complexes: evidence that C5a is generated intravascularly during heparin--protamine interaction. , 1983, Clinical immunology and immunopathology.

[3]  M. Kazatchkine,et al.  Modulation of the formation of the human amplification C3 convertase of complement by polycations. , 1983, Immunology.

[4]  S Westaby,et al.  Complement and the damaging effects of cardiopulmonary bypass. , 1983, Thorax.

[5]  C. Wildevuur,et al.  Two membrane oxygenators and a bubbler: a clinical comparison. , 1983, The Annals of thoracic surgery.

[6]  M. Cohen,et al.  A defect in the oxidative metabolism of human polymorphonuclear leukocytes that remain in circulation early in hemodialysis. , 1982, Blood.

[7]  M. Loos.  The classical complement pathway: mechanism of activation of the first component by antigen-antibody complexes. , 1982, Progress in allergy.

[8]  R. Golub,et al.  Chemiluminescence in microamounts of whole blood for investigation of the human phagocyte oxidative metabolism function. , 1982, Annales d'immunologie.

[9]  P. Lambert,et al.  Decreased capacity to solubilize immune complexes in sera from patients with systemic lupus erythematosus. , 1981, Arthritis and rheumatism.

[10]  K. Skubitz,et al.  Reversal of hemodialysis granulocytopenia and pulmonary leukostasis: A clinical manifestation of selective down-regulation of granulocyte responses to C5adesarg. , 1981, The Journal of clinical investigation.

[11]  G. Im.  Chemotactic factor receptors on leukocytes--scratching the surface. , 1981 .

[12]  J. Roth,et al.  Cell-mediated immunity is depressed following cardiopulmonary bypass. , 1981, The Annals of thoracic surgery.

[13]  D. Stroncek,et al.  Complement activation and neutropenia occurring during cardiopulmonary bypass. , 1981, The Journal of thoracic and cardiovascular surgery.

[14]  E. Blackstone,et al.  Complement activation during cardiopulmonary bypass: evidence for generation of C3a and C5a anaphylatoxins. , 1981, The New England journal of medicine.

[15]  M. Daha,et al.  Interaction between human neutrophils and zymosan particles: the role of opsonins and divalent cations. , 1981, Journal of immunology.

[16]  M. J. Moore,et al.  Complement-induced granulocyte aggregation: an unsuspected mechanism of disease. , 1980, The New England journal of medicine.

[17]  H. Müller-Eberhard,et al.  C3e: an acidic fragment of human C3 with leukocytosis-inducing activity. , 1979, Journal of immunology.

[18]  J. Fierer,et al.  Deficient serum bactericidal activity against Escherichia coli in patients with cirrhosis of the liver. , 1979, The Journal of clinical investigation.

[19]  R. Zubler,et al.  Decreased heat-labile opsonic activity and complement levels associated with evidence of C3 breakdown products in infected pleural effusions. , 1979, The Journal of clinical investigation.

[20]  R S Kronenberg,et al.  Complement and leukocyte-mediated pulmonary dysfunction in hemodialysis. , 1977, The New England journal of medicine.

[21]  J. Weiler,et al.  Pathways of complement activation in membranoproliferative glomerulonephritis and allograft rejection. , 1977, Transplantation proceedings.

[22]  J. Weiler,et al.  Control of the amplification convertase of complement by the plasma protein beta1H. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[23]  G. Barnett,et al.  Acute postoperative renal failure in cardiac surgical patients. , 1976, The Journal of surgical research.

[24]  V. Nussenzweig,et al.  Studies on the mechanism of solubilization of immune precipitates by serum , 1976, The Journal of experimental medicine.

[25]  J. Rahal,et al.  Host resistance to Serratia marcescens infection: serum bactericidal activity and phagocytosis by normal blood leukocytes. , 1976, The Journal of laboratory and clinical medicine.

[26]  H. Gewurz,et al.  Complement activation by interaction of polyanions and polycations. , 1975, Immunology.

[27]  J. White,et al.  The influence of phorbol myristate acetate on oxygen consumption by polymorphonuclear leukocytes. , 1974, The Journal of laboratory and clinical medicine.

[28]  T. Stossel,et al.  Evaluation of opsonic and leukocyte function with a spectrophotometric test in patients with infection and with phagocytic disorders. , 1973, Blood.

[29]  F. Rossi,et al.  Reversible metabolic stimulation of polymorphonuclear leukocytes and macrophages by concanavalin A. , 1973, Nature: New biology.

[30]  S. Ruddy,et al.  Alternate complement pathway: factors involved in cobra venom factor (CoVF) activation of the third component of complement (C3). , 1973, Journal of immunology.

[31]  L. Young,et al.  Human immunity to Pseudomonas aeruginosa. II. Relationship between heat-stable opsonins and type-specific lipopolysaccharides. , 1972, The Journal of infectious diseases.

[32]  Karp Rb,et al.  Changes in serum complement and immunoglobulins following cardiopulmonary bypass. , 1972 .

[33]  E. Miller,et al.  Leucocyte mobilizing factor: A new biological activity derived from the third component of complement , 1971, European journal of immunology.

[34]  R. Stroud,et al.  Blood Damage in the Heart-Lung Machine , 1971 .

[35]  D. McGoon,et al.  Bleeding patterns after open-heart surgery. , 1970, The Journal of thoracic and cardiovascular surgery.

[36]  J. Goffinet,et al.  Profound neutropenia during the early phase of hemodialysis. , 1968, JAMA.

[37]  W. Krivit,et al.  Problems in hemostasis during openheart surgery. IV. On the changes in the blood clotting mechanism during cardiopulmonary bypass procedures. , 1962, Annals of surgery.

[38]  M L KARNOVSKY,et al.  The biochemical basis of phagocytosis. I. Metabolic changes during the ingestion of particles by polymorphonuclear leukocytes. , 1959, The Journal of biological chemistry.

[39]  M. Kazatchkine,et al.  Complement-Mediated Injury , 1986 .

[40]  D. Chenoweth.  Biocompatibility of hemodialysis membranes: evaluation with C3a anaphylatoxin radioimmunoassays , 1984 .

[41]  M. Kazatchkine,et al.  The Human Alternative Complement Pathway : Biology and Immunopathology of Activation and Regulation1 , 1982 .

[42]  C. Wildevuur,et al.  Clinical study of blood trauma during perfusion with membrane and bubble oxygenators. , 1982, The Journal of thoracic and cardiovascular surgery.

[43]  C. Wildevuur.  Towards safer cardiopulmonary bypass , 1981 .

[44]  M. Kazatchkine,et al.  Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase. , 1981, The Journal of clinical investigation.

[45]  H. T. ten Duis,et al.  Improved hemocompatibility in open heart surgery. , 1978, Transactions - American Society for Artificial Internal Organs.

[46]  J. C. F. de Jong,et al.  Hematologic abnormalities in extracorporeal circuits (ECC) , 1976 .

[47]  H. Gewurz,et al.  Complement activation by interaction of polyanions and polycations. I. Heparin-protamine induced consumption of complement. , 1975, Journal of immunology.